Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

AIDS

Volumn 23, Issue 1, 2009, Pages 95-99

  Wirden, Marc ^a   Lambert Niclot, Sidonie ^a   Marcelin, Anne Genevieve ^a   Schneider, Luminita ^a   Ait Mohand, Hocine ^a   Brunet, Christel ^a   Angleraud, Francis ^a   Amard, Sylvain ^a   Katlama, Christine ^a   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Abacavir; Efavirenz; K103N; L74I; L74V; Tenofovir; Zidovudine

Indexed keywords

ABACAVIR; ABACAVIR PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; L74I GENE; L74V GENE; MAJOR CLINICAL STUDY; MUTATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 58149105363     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328319bc91     Document Type: Article

References (13)

1. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000; 181:912-920.
2. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121:263-268.
3. Marcelin AC, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-1744.
4. Masqueli er B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 2004; 9:315-323.
5. Miranda LR, Gotte M, Liang F, Kuritzkes DR. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005; 49:2648-2656.
6. Berkhout B, Back NK, de Ronde A, Jurriaans S, Bakker M, Parkin NT, van der Hoek L. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS 2006; 20:1515-1520.
7. Wirden M, Roquebert B, Derache A, Simon A, Duvivier C, Ghosn J, et al. Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2006; 50: 2553-2556.
8. Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74->Val or Ile and Val-75->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A 1996; 93:34-38.
9. Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology 2006; 353:184-192.
10. Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004; 5:394-399.
11. Delaugerre C, Rohban R, Simon A, Mouroux M, Agher R, Katlama C, et al. Resistance profile and cross-resistance of HIV-1 among 104 patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448.
12. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
13. Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids 2008; 22:367-376.